Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)
Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial
The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:
- Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
- What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.
Participants will be randomized to one of two treatment strategies:
- Experimental group: Surgical excision of the labial venous malformation (VM).
- Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.
Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.
Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.
Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Aline JOLY, MD
- 电话号码:+332 47 47 38 21
- 邮箱:a.joly@chu-tours.fr
研究联系人备份
- 姓名:Coralie TAILLEBUIS
- 电话号码:+33247473909
- 邮箱:c.taillebuis@chu-tours.fr
学习地点
-
-
-
Paris、法国
- Lariboisière
-
接触:
- Annouk BISDORFF, MD
- 电话号码:+331 49 95 84 50
- 邮箱:annouk.bisdorff@aphp.fr
-
接触:
-
首席研究员:
- Annouk BISDORFF, MD
-
Paris、法国
- Necker
-
接触:
- Olivia BOCCARA, MD
- 电话号码:+331 44 49 46 63
- 邮箱:olivia.boccara@aphp.fr
-
首席研究员:
- Olivia BOCCARA, MD
-
Tours、法国
- CHRU de Tours
-
接触:
- Aline JOLY, MD
- 电话号码:+332 47 47 38 21
- 邮箱:a.joly@chu-tours.fr
-
接触:
-
首席研究员:
- Aline JOLY, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 4 years
- Symptomatic venous malformation of the lower and/or upper lip
- Venous pocket with an area of between 10 and 50 mm²
- No history of surgery or interventional radiology in the area within the two years prior to inclusion
- Suitable for sclerotherapy and surgery
- Patient covered by the National Health Service
- Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age
Exclusion Criteria:
- Pregnant or breastfeeding women
- Women of childbearing age not using effective contraception throughout the study
- Patients under guardianship or curatorship, or subject to a court-ordered protective measure
- Other vascular abnormalities
- Contraindications to MRI
- Contraindications to Aetoxisclerol®
- Contraindications to general anaesthesia
- Contraindications to surgery
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Surgical strategy
Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects. |
The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis. |
|
有源比较器:Sclerotherapy strategy
Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol). |
The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops. Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Global change
大体时间:From enrollment to Month 12 post intervention
|
Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint). |
From enrollment to Month 12 post intervention
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Aesthetic impact of the venous malformation
大体时间:Month 0 and Month 12
|
Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention. |
Month 0 and Month 12
|
|
Functional impact: overall mouth function
大体时间:Month 0 and Month 12
|
Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: lip continence
大体时间:Month 0 and Month 12
|
Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: speech intelligibility
大体时间:Month 0 and Month 12
|
Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome |
Month 0 and Month 12
|
|
Overall patient satisfaction: Likert scale
大体时间:From enrollment to Month 12
|
Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome |
From enrollment to Month 12
|
|
Overall patient satisfaction: Goal Attainment Scale
大体时间:Month 12
|
Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005). |
Month 12
|
|
Number of painful days: Total number of painful days
大体时间:The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
Total number of painful days assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
|
Number of painful days: Number of painful days with a VAS pain score > 3/10
大体时间:The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
|
Venous Malformation volume on MRI
大体时间:Month 0 and Month 12
|
Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation. |
Month 0 and Month 12
|
|
Coagulation: D-dimer
大体时间:Month 12
|
D-dimer |
Month 12
|
|
Coagulation: fibrinogen level
大体时间:Month 12
|
Fibrinogen level |
Month 12
|
|
Adverse events including complications
大体时间:From enrollment to Month 12
|
Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal |
From enrollment to Month 12
|
|
Acceptability of the interventions
大体时间:Month 1, Month 3 , and Month 12
|
Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome |
Month 1, Month 3 , and Month 12
|
|
Healthcare costs
大体时间:From enrollment to Month 12 following the intervention
|
In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system. |
From enrollment to Month 12 following the intervention
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- DR240317
- 2025 (美国 NIH 拨款/合同)
- 2025-521374-34-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.